Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
about
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenA simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Antituberculosis drugs in children.A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.Population Pharmacokinetics of the Antimalarial Amodiaquine: A Pooled Analysis to Optimize DosingExtrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale
P2860
Q35215680-1AC878E1-74E7-47A5-AB16-477896D8B967Q35742101-847D3CB2-EBC2-4C96-93F2-FC89895BB0E4Q36706812-E79212D6-B391-462B-9901-782EAF53C23FQ37120112-D6F7A07D-42E0-4338-AF9E-88F962ACB68BQ37339294-4EA5F982-4565-444E-8B6B-846690C3AEF6Q38533435-FE604C91-A5E1-4B2E-B0E7-77698651016DQ38547708-D4418ACE-16C7-4A40-8F6B-997B790ED6C8Q40260228-05647590-D575-4282-BC08-7BB7D3E09D73Q47778426-AEFF9CE3-1C78-4DB6-AA0B-79D3F7154615Q48287062-3EFA93AE-2147-4052-9879-CEA8D3591053Q56358106-EABA3B2D-F724-44DC-943A-54816A8AFD79Q58738240-489290EE-3808-4DA7-A9F9-67C706EB9FB3
P2860
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetics of ...... of currently recommended doses
@en
Population pharmacokinetics of ...... f currently recommended doses.
@nl
type
label
Population pharmacokinetics of ...... of currently recommended doses
@en
Population pharmacokinetics of ...... f currently recommended doses.
@nl
prefLabel
Population pharmacokinetics of ...... of currently recommended doses
@en
Population pharmacokinetics of ...... f currently recommended doses.
@nl
P2093
P2860
P50
P356
P1476
Population pharmacokinetics of ...... of currently recommended doses
@en
P2093
Heiner I Seifart
James A Seddon
Peter J Smith
Peter R Donald
Simbarashe P Zvada
Stephanie Thee
P2860
P304
P356
10.1093/JAC/DKT524
P407
P577
2014-01-31T00:00:00Z